● neutral
Impact
PhasePreclinical (Phase 1 imminent)
Time to marketMultiple years if successful. The drug has not yet entered Phase 1. Assuming positive Phase 1 results and a Phase 2 start in 2H 2027, Phase 3 trials would follow, putting a potential approval at earliest several years out (likely 2030+).
EVO570 vav1 molecular glue degrader Updated Nov 6
What to watch
The key near-term event to watch is the formal announcement of Phase 1 first-patient-dosed (expected January 2027). A successful start would signal the molecule is safe enough for human testing. The more consequential catalyst will be Phase 1 safety and PK/PD data around mid-2027, which will provide the first human proof-of-mechanism for VAV1 degradation. Investors should also monitor how the Phase 2 Sjogren's data for Novartis' competing VAV1 degrader MRT-6160 reads out, as positive results would validate the target but also increase competitive pressure.
Bull case
- EVO570 targets a novel, well-validated immune target (VAV1) with a differentiated mechanism (molecular glue degradation) that Novartis validated with a $150M+ upfront deal and its own Phase 2 entry, suggesting the biology is real.
- Preclinical data show sub-nanomolar potency, high selectivity, and once-daily oral dosing with activity across multiple autoimmune disease models, which Evommune management describes as potentially best-in-class.
- The $30M upfront cost is modest relative to the $1.1B biobucks framework and similar Novartis/Monte Rosa deals, giving Evommune asymmetric upside if the drug succeeds.
Bear case
- The drug is still preclinical with zero human data; most preclinical assets fail to translate into safe and effective human therapies.
- The VAV1 degrader space is already competitive: Novartis' MRT-6160 (DDY391) from Monte Rosa is in Phase 2 for Sjogren's disease, and Novartis has far greater resources to develop and commercialize.
- Evommune's credibility is damaged after EVO756 failed its Phase 2b atopic dermatitis trial in September 2026, missing the primary endpoint and all secondaries, and the company has not yet demonstrated an ability to execute on complex clinical programs.